Anita B.
- Country
- Hungary
- Department
- Onkoradiológiai Osztály
Research Overview
- A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
- An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Data & Insights
Has run more than one trial at 42 of 225 partner sites.
Specializations
Oncology Focus
The investigator specializes in treating advanced tumors and clear cell renal cell carcinoma (ccRCC), with particular emphasis on innovative therapeutic approaches.
- Advanced Tumor Management
- Renal Cancer Treatment
- First-line Therapeutic Strategies
Their clinical interests encompass the assessment of survival outcomes in cancer patients.
Treatment Approaches
The investigator focuses on immune and targeted combination therapies as primary treatment modalities for advanced cancers.
- Immunotherapy Applications
- Combination Treatment Strategies
- Response Evaluation
Their work involves evaluating treatment efficacy through specialized assessment criteria and independent review processes.
Clinical Outcomes
The investigator specializes in measuring critical endpoints including progression-free survival (PFS) and overall survival (OS) in cancer patients.
- Survival Analysis
- Disease Progression Assessment
- Treatment Response Monitoring
Their expertise includes evaluating therapeutic outcomes through standardized criteria such as RECIST 1.1.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.